Mabwell-B Shares Surge Following FDA Clearance for Clinical Trial of Novel Drug Candidate

Stock News05-11

Mabwell-B (02493) saw its shares rise nearly 5% in the afternoon session. At the time of writing, the stock was up 3.54%, trading at HKD 27.52 with a turnover of HKD 33.26 million.

The increase follows the company's announcement that the U.S. Food and Drug Administration (FDA) has approved the clinical trial application for its self-developed novel antibody drug, 9MW5211, for the treatment of Inflammatory Bowel Disease (IBD).

Furthermore, clinical trial applications for 9MW5211 targeting multiple indications, including IBD and Multiple Sclerosis (MS), have already been accepted for review by China's National Medical Products Administration (NMPA).

9MW5211 is reported to be the world's first candidate drug targeting its specific mechanism to enter the clinical stage.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment